WHWK (Aadi Bio) קצב צמיחת רווח למניה בשנה הנוכחית

Aadi Bioscience Inc (WHWK) profitability is based on the sales of FYARRO in oncology centers and the expansion of its application. The YoY earnings per share growth rate demonstrates a sustainable trend, where the current metric is -185.60. High margins are supported by albumin nanoparticles and the patent for PEComa treatment, while the orphan drug status creates a barrier for new entrants due to the high cost of testing.

Aadi Bioscience Inc (WHWK) utilizes an outsourcing model for development and production to minimize capital expenditures. This approach directly impacts the comparable year-over-year growth rate of earnings per share, which measures the dynamics of net income per share. This metric reflects the efficiency of operating expense management relative to previous periods. Analyzing the trajectory of this indicator allows for an assessment of the business's financial stability. Investors use this indicator to verify the scalability of the scientific model.